Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swiss (SMI) Pharma Industry Analysis

UpdatedMay 24, 2026
DataAggregated Company Financials
Companies9
  • 7D2.7%
  • 3M-7.2%
  • 1Y31.8%
  • YTD5.7%

Over the last 7 days, the Pharma industry has risen 2.7%, driven by gains from Roche Holding of 3.6%. This takes the industry's 12 month performance to a gain of 32%. Earnings are forecast to grow by 10% annually.

Industry Valuation and Performance

Has the Swiss Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 24 May 2026CHF 566.3bCHF 121.2bCHF 24.8b38.9x22.8x4.7x
Tue, 21 Apr 2026CHF 553.8bCHF 120.8bCHF 25.0b38.9x22.1x4.6x
Thu, 19 Mar 2026CHF 551.7bCHF 121.8bCHF 25.3b37.3x21.8x4.5x
Sat, 14 Feb 2026CHF 597.5bCHF 119.3bCHF 24.2b35.9x24.6x5x
Mon, 12 Jan 2026CHF 582.1bCHF 121.5bCHF 21.6b36.2x27x4.8x
Wed, 10 Dec 2025CHF 545.9bCHF 121.8bCHF 21.7b33.9x25.2x4.5x
Fri, 07 Nov 2025CHF 487.0bCHF 121.9bCHF 21.7b32x22.5x4x
Sun, 05 Oct 2025CHF 508.8bCHF 120.1bCHF 20.9b33.5x24.3x4.2x
Tue, 02 Sep 2025CHF 480.2bCHF 120.4bCHF 21.0b30.4x22.9x4x
Thu, 31 Jul 2025CHF 464.2bCHF 121.2bCHF 21.0b23.4x22.1x3.8x
Sat, 28 Jun 2025CHF 450.4bCHF 117.5bCHF 19.0b25.1x23.8x3.8x
Mon, 26 May 2025CHF 436.0bCHF 118.8bCHF 19.2b25x22.7x3.7x
Wed, 23 Apr 2025CHF 412.3bCHF 117.5bCHF 18.4b24.5x22.4x3.5x
Fri, 21 Mar 2025CHF 485.5bCHF 121.6bCHF 19.1b29.4x25.4x4x
Sun, 16 Feb 2025CHF 475.3bCHF 122.4bCHF 19.1b22.9x24.9x3.9x
Tue, 14 Jan 2025CHF 440.8bCHF 120.3bCHF 21.5b18.3x20.5x3.7x
Thu, 12 Dec 2024CHF 423.4bCHF 117.9bCHF 21.1b18.1x20x3.6x
Sat, 09 Nov 2024CHF 439.1bCHF 117.4bCHF 21.0b18.9x20.9x3.7x
Mon, 07 Oct 2024CHF 445.7bCHF 115.4bCHF 19.4b21.1x23x3.9x
Wed, 04 Sep 2024CHF 471.2bCHF 114.9bCHF 19.3b22.5x24.4x4.1x
Fri, 02 Aug 2024CHF 467.4bCHF 116.5bCHF 19.7b22.6x23.8x4x
Sun, 30 Jun 2024CHF 434.0bCHF 116.4bCHF 19.8b33.7x21.9x3.7x
Tue, 28 May 2024CHF 410.2bCHF 117.4bCHF 19.9b42.7x20.6x3.5x
Thu, 25 Apr 2024CHF 394.2bCHF 113.7bCHF 20.0b37.3x19.7x3.5x
Sat, 23 Mar 2024CHF 386.2bCHF 111.7bCHF 19.3b37.5x20x3.5x
Mon, 19 Feb 2024CHF 380.8bCHF 110.4bCHF 19.7b23.9x19.3x3.4x
Wed, 17 Jan 2024CHF 416.8bCHF 120.0bCHF 18.7b27.2x22.2x3.5x
Fri, 15 Dec 2023CHF 397.8bCHF 120.2bCHF 18.8b25x21.2x3.3x
Sun, 12 Nov 2023CHF 385.0bCHF 122.6bCHF 19.1b23.4x20.2x3.1x
Tue, 10 Oct 2023CHF 407.0bCHF 121.8bCHF 18.7b26.3x21.8x3.3x
Thu, 07 Sep 2023CHF 395.6bCHF 112.4bCHF 18.0b47.6x22x3.5x
Sat, 05 Aug 2023CHF 409.2bCHF 114.6bCHF 19.2b48.3x21.3x3.6x
Mon, 03 Jul 2023CHF 421.0bCHF 115.1bCHF 18.9b36.9x22.3x3.7x
Wed, 31 May 2023CHF 426.7bCHF 115.6bCHF 18.9b38.4x22.5x3.7x
Price to Earnings Ratio

22.5x


Total Market Cap: CHF 426.7bTotal Earnings: CHF 18.9bTotal Revenue: CHF 115.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swiss Pharma Industry Price to Earnings3Y Average 22.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Swiss Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 22.5x.
  • The 3-year average PS ratio of 3.9x is lower than the industry's current PS ratio of 4.7x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 9.4% per year over the last three years, while revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since profits are increasing while sales have been flat.

Industry Trends

Which industries have driven the changes within the Swiss Healthcare industry?

CH Market1.83%
Healthcare3.31%
Pharma2.68%
Pharma2.68%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
ROP Roche HoldingCHF 334.503.6%
+CHF 9.3b		28.7%PE20.7x
NOVN NovartisCHF 119.462.4%
+CHF 5.3b		28.8%PE21.5x
GALD Galderma GroupCHF 158.651.3%
+CHF 469.1m		55.2%PE77.4x
DESN Dottikon ES HoldingCHF 363.001.5%
+CHF 76.0m		75.4%PE41.5x
COPN CosmoCHF 78.102.5%
+CHF 30.8m		39.5%PS13.3x

Latest News

GALD
CHF 158.65
Galderma Group
7D
1.3%
1Y
55.2%
NOVN
CHF 119.46
Novartis
7D
2.4%
1Y
28.8%
Narrative Update • May 21

NOVN: Expanded Therapies And Manufacturing Will Support Balanced Outlook And Dividend

Analysts have raised their Novartis price target slightly to CHF122.04 from CHF120.89, reflecting updated views on revenue growth, profit margins and the P/E multiple used in their models. What's in the News Pluvicto plus standard of care in the Phase III PSMAddition trial in PSMA positive metastatic hormone sensitive prostate cancer showed a 58% lower risk of PSA progression versus standard care alone, with a higher proportion of patients reaching deep PSA reductions at weeks 12, 24 and 48, and regulatory filings submitted in the US, China and Japan (Product related announcement).
ROP
CHF 334.50
Roche Holding
7D
3.6%
1Y
28.7%
DESN
CHF 363.00
Dottikon ES Holding
7D
1.5%
1Y
75.4%
Analysis Article • May 17

Here's Why Dottikon ES Holding (VTX:DESN) Has Caught The Eye Of Investors

It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
COPN
CHF 78.10
Cosmo
7D
2.5%
1Y
39.5%
Narrative Update • May 16

Cosmo Pharmaceuticals Will Achieve Its Target Price of €95–110 in 12 Months

Below is a full institutional-style comps + valuation (target price) for Cosmo Pharmaceuticals N.V. , integrating: ✅ FY2025 audited report (your PDF) ✅ Product + pipeline positioning (Cosmo site + report) ✅ Sell-side-style benchmarking framework (SWS-type approach: specialty pharma + medtech AI comps) 1) Investment framing (key drivers) Business mix (unique hybrid) Cosmo is a multi-vertical life sciences platform : MedTech AI (GI Genius™) → high-growth SaaS/MedTech multiple Dermatology (Winlevi + Clascoterone) → specialty pharma growth GI pharma + royalties (MMX platform) → stable cash flows CDMO → low multiple, stabilizer Important: market struggles to value hybrid → mispricing opportunity 2) Financial baseline (FY2025) Core metrics Revenue: €104.2m Recurring revenue: €88.1m (+15%) EBITDA: €9.5m Net income: –€3.5m Cash + investments: €128.3m Market cap: €1.98bn 2025 distorted due to: loss of €186m Medtronic milestone (2024) underlying recurring growth intact (+15%) 3) Product + pipeline valuation bridge A. Commercial assets (anchor value) 1.
SDZ
CHF 64.44
Sandoz Group
7D
-1.6%
1Y
59.2%
NWRN
CHF 14.04
Newron Pharmaceuticals
7D
-1.3%
1Y
90.2%
New Narrative • May 10

Still A Binary Phase III Bet on Evenamide

Rating: Speculative Buy / Clinical-event driven Style: Small-cap biotech with one dominant value driver Core debate: Is Newron an underappreciated CNS biotech on the verge of a value inflection with evenamide, or is it still a one-asset, high-risk Phase III story where financing and trial execution dominate everything else? Executive view Newron is now essentially an evenamide company.
BIOV
CHF 27.00
BioVersys
7D
0.4%
1Y
-22.0%
ADXN
CHF 0.047
Addex Therapeutics
7D
4.9%
1Y
-18.6%
CURN
CHF 23.90
Curatis Holding
7D
5.8%
1Y
78.4%